Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615056 | 0.91 | AVPR1A (0.57) | MEN1KMT2AALDH1A1MAPTNPSR1 | |
| SCHEMBL613528 | 0.91 | MEN1 (0.55) | MEN1KMT2AALDH1A1MAPTNPSR1 | |
| SCHEMBL615061 | 0.90 | CNR1 (0.47) | MEN1KMT2AALDH1A1MAPTCNR1 | |
| SCHEMBL3046434 | 0.89 | MEN1 (0.57) | MEN1KMT2AALDH1A1MAPTNPSR1 | |
| SCHEMBL613480 | 0.89 | MEN1 (0.53) | MEN1KMT2AALDH1A1MAPTNPSR1 | |
| SCHEMBL615558 | 0.89 | AVPR1A (0.58) | MEN1KMT2AALDH1A1MAPTNPSR1 | |
| SCHEMBL615240 | 0.89 | MGLL (0.47) | MEN1KMT2ACNR1AVPR1AMGLL | |
| SCHEMBL612386 | 0.89 | MEN1 (0.56) | MEN1KMT2AALDH1A1MAPTNPSR1 | |
| SCHEMBL613260 | 0.88 | MEN1 (0.52) | MEN1KMT2AALDH1A1MAPTNPSR1 | |
| SCHEMBL614143 | 0.88 | AVPR1A (0.57) | MEN1KMT2AALDH1A1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040990-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | BISSANTZ CATERINA (FR) | 2012-02-16 | — | — | US | disclosed |
| EP-2392571-A2 | Indol-3-yl-carbonyl-piperidin and piperazin derivatives | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| US-20100222357-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | BISSANTZ CATERINA | 2010-09-02 | — | — | US | disclosed |
| US-7781436-B2 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-08-24 | — | — | US | disclosed |
| EP-1917255-A2 | INDOL-3-YL-CARBONYL-PIPERIDIN AND PIPERAZIN DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007014851-A2 | INDOL-3-YL-CARBONYL-PIPERIDIN AND PIPERAZIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027163-A1 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222357-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | AVPR1A, AVPR2, OXTR | MEN1 1220/4885KMT2A 1967/4885ALDH1A1 1370/4885 |
| US-20120040990-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | AVPR1A, AVPR2, OXTR | MEN1 1220/4885KMT2A 1967/4885ALDH1A1 1370/4885 |
| US-20070027163-A1 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | AVPR1A, AVPR2, OXTR | MEN1 1220/4885KMT2A 1967/4885ALDH1A1 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.